These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

268 related articles for article (PubMed ID: 21323910)

  • 1. The dual neuroprotective-neurotoxic profile of cannabinoid drugs.
    Sarne Y; Asaf F; Fishbein M; Gafni M; Keren O
    Br J Pharmacol; 2011 Aug; 163(7):1391-401. PubMed ID: 21323910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Beneficial and deleterious effects of cannabinoids in the brain: the case of ultra-low dose THC.
    Sarne Y
    Am J Drug Alcohol Abuse; 2019; 45(6):551-562. PubMed ID: 30864864
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cannabinoids: between neuroprotection and neurotoxicity.
    Sarne Y; Mechoulam R
    Curr Drug Targets CNS Neurol Disord; 2005 Dec; 4(6):677-84. PubMed ID: 16375685
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Are cannabinoid drugs neurotoxic or neuroprotective?
    Sarne Y; Keren O
    Med Hypotheses; 2004; 63(2):187-92. PubMed ID: 15236773
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease.
    Lastres-Becker I; Molina-Holgado F; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Neurobiol Dis; 2005; 19(1-2):96-107. PubMed ID: 15837565
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A single low dose of tetrahydrocannabinol induces long-term cognitive deficits.
    Tselnicker I; Keren O; Hefetz A; Pick CG; Sarne Y
    Neurosci Lett; 2007 Jan; 411(2):108-11. PubMed ID: 17092651
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Ultralow doses of cannabinoid drugs protect the mouse brain from inflammation-induced cognitive damage.
    Fishbein-Kaminietsky M; Gafni M; Sarne Y
    J Neurosci Res; 2014 Dec; 92(12):1669-77. PubMed ID: 25042014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pre- and post-conditioning treatment with an ultra-low dose of Δ9-tetrahydrocannabinol (THC) protects against pentylenetetrazole (PTZ)-induced cognitive damage.
    Assaf F; Fishbein M; Gafni M; Keren O; Sarne Y
    Behav Brain Res; 2011 Jun; 220(1):194-201. PubMed ID: 21315768
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dual neuroprotective and neurotoxic effects of cannabinoid drugs in vitro.
    Bologov A; Gafni M; Keren O; Sarne Y
    Cell Mol Neurobiol; 2011 Mar; 31(2):195-202. PubMed ID: 21052827
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cannabis, Cannabinoids, and Brain Morphology: A Review of the Evidence.
    Chye Y; Kirkham R; Lorenzetti V; McTavish E; Solowij N; Yücel M
    Biol Psychiatry Cogn Neurosci Neuroimaging; 2021 Jun; 6(6):627-635. PubMed ID: 32948510
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cannabinoids and neuronal damage: differential effects of THC, AEA and 2-AG on activated microglial cells and degenerating neurons in excitotoxically lesioned rat organotypic hippocampal slice cultures.
    Kreutz S; Koch M; Ghadban C; Korf HW; Dehghani F
    Exp Neurol; 2007 Jan; 203(1):246-57. PubMed ID: 17010339
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties.
    García-Arencibia M; González S; de Lago E; Ramos JA; Mechoulam R; Fernández-Ruiz J
    Brain Res; 2007 Feb; 1134(1):162-70. PubMed ID: 17196181
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analogues of cannabinoids as multitarget drugs in the treatment of Alzheimer's disease.
    Sánchez Montero JM; Agis-Torres A; Solano D; Söllhuber M; Fernandez M; Villaro W; Gómez-Cañas M; García-Arencibia M; Fernández-Ruiz J; Egea J; Martín MI; Girón R
    Eur J Pharmacol; 2021 Mar; 895():173875. PubMed ID: 33460612
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic effects of cannabinoids in animal models of seizures, epilepsy, epileptogenesis, and epilepsy-related neuroprotection.
    Rosenberg EC; Patra PH; Whalley BJ
    Epilepsy Behav; 2017 May; 70(Pt B):319-327. PubMed ID: 28190698
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of cannabinoids Δ(9)-tetrahydrocannabinol, Δ(9)-tetrahydrocannabinolic acid and cannabidiol in MPP+ affected murine mesencephalic cultures.
    Moldzio R; Pacher T; Krewenka C; Kranner B; Novak J; Duvigneau JC; Rausch WD
    Phytomedicine; 2012 Jun; 19(8-9):819-24. PubMed ID: 22571976
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Therapeutic potential of cannabinoids in CNS disease.
    Croxford JL
    CNS Drugs; 2003; 17(3):179-202. PubMed ID: 12617697
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cannabinoid disruption of learning mechanisms involved in reward processing.
    Lupica CR; Hoffman AF
    Learn Mem; 2018 Sep; 25(9):435-445. PubMed ID: 30115765
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prevention of Alzheimer's disease pathology by cannabinoids: neuroprotection mediated by blockade of microglial activation.
    Ramírez BG; Blázquez C; Gómez del Pulgar T; Guzmán M; de Ceballos ML
    J Neurosci; 2005 Feb; 25(8):1904-13. PubMed ID: 15728830
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Neuroprotective antioxidants from marijuana.
    Hampson AJ; Grimaldi M; Lolic M; Wink D; Rosenthal R; Axelrod J
    Ann N Y Acad Sci; 2000; 899():274-82. PubMed ID: 10863546
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Neuroprotective mechanisms of cannabinoids in brain ischemia and neurodegenerative disorders].
    Osuna-Zazuetal MA; Ponce-Gómez JA; Pérez-Neri I
    Invest Clin; 2015 Jun; 56(2):188-200. PubMed ID: 26299059
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.